2 Information about fremanezumab

Marketing authorisation indication

2.1 Fremanezumab (Ajovy, Teva Pharmaceuticals) is indicated for 'prophylaxis of migraine in adults who have at least 4 migraine days per month'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for fremanezumab.


2.3 The price of fremanezumab is £450.00 per 225‑mg injection (£1,350 per 675 mg) excluding VAT; BNF online, accessed November 2021. The company has a commercial arrangement. This makes fremanezumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)